Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Acceptance and Commitment Therapy × Clear all

Phase

Phase NA 20 Phase EARLY_PHASE1 1 Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cancer Recurrence 1

Interventions

Cyclophosphamide 559 pembrolizumab 434 Paclitaxel 398 Gemcitabine 384 Cisplatin 379 Carboplatin 377 Radiotherapy 339 fludarabine 318 Nivolumab 298 Bevacizumab 247 Docetaxel 242 Irinotecan 219 Magnetic Resonance Spectroscopy 213 Fluorouracil 200 Dexamethasone 200 Specimen Handling 194 Capecitabine 192 Rituximab 182 Cytarabine 181 Oxaliplatin 176 fludarabine phosphate 174 Temozolomide 172 Biopsy 171 Ipilimumab 166 Lenalidomide 162 Etoposide 162 Doxorubicin 153 Leucovorin 151 Cetuximab 151 Bortezomib 149

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01354041 2014-01-27

WiLLoW

University of California, San Francisco

Phase 1 Completed

Cancer Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡